白蛋白 - 胆红素（ALBI）作为慢性乙型肝炎相关肝硬化的准确

StephenW

Dig Liver Dis. 2019 Jan 26. pii: S1590-8658(19)30039-8. doi: 10.1016/j.dld.2019.01.011. [Epub ahead of print]
Albumin-Bilirubin (ALBI) as an accurate and simple prognostic score for chronic hepatitis B-related liver cirrhosis.
Wang J1, Zhang Z1, Yan X1, Li M2, Xia J1, Liu Y3, Chen Y3, Jia B1, Zhu L2, Zhu C4, Huang R5, Wu C6.
Author information

1
    Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.
2
    Department of Hepatology, The Fifth People's Hospital of Suzhou, Suzhou, Jiangsu, China.
3
    Department of Laboratory Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.
4
    Department of Hepatology, The Fifth People's Hospital of Suzhou, Suzhou, Jiangsu, China. Electronic address: [email protected].
5
    Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China. Electronic address: [email protected].
6
    Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China. Electronic address: [email protected].

Abstract
BACKGROUND:

The Albumin-Bilirubin (ALBI) score was developed to predict the long-term prognosis of hepatocellular carcinoma patients. We aimed to investigate the performance of ALBI for predicting severity and long-term prognosis of chronic hepatitis B-related liver cirrhosis (CHB-LC).
METHODS:

CHB-LC patients were enrolled from two medical centers between 2011 and 2017. The prognostic performance of ALBI was evaluated and compared with Child-Turcotte-Pugh (CTP), model of end-stage liver disease (MELD) and MELD integrating sodium (MELD-Na) scores.
RESULTS:

This study enrolled 398 CHB-LC patients and patients were followed up for a median of 33.9 (IQR 21.6-48.8) months. The ALBI (HR: 3.151, 95% CI: 2.039-4.869,P < 0.001) was identified as an independent predictor of liver-related mortality. The receiver operating characteristic curves (ROCs) analysis revealed that ALBI score (0.756, 0.745, 0.739, 0.767 and 0.765) was superior to MELD score (P < 0.05) and comparable with CTP score (P > 0.05) for predicting 2-year, 3-year, 4-year, 5-year and global mortality. The AUROCs of ALBI score were significantly higher than MELD-Na score(P < 0.05) for predicting 2-year, 3-year and 5-year mortality. Patients with lower ALBI grade had a significantly lower mortality than patients with higher ALBI grade (P < 0.05).
CONCLUSIONS:

ALBI score accurately predicts the severity and long-term prognosis of patients with CHB-LC. The prognostic performance of ALBI score was superior to MELD and MELD-Na score.

Copyright © 2019 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
KEYWORDS:

ALBI; CHB; Mortality; Noninvasive markers; Prediction

PMID:
    30765220
DOI:
    10.1016/j.dld.2019.01.011

StephenW

Dig Liver Dis。 2019年1月26日.pii：S1590-8658（19）30039-8。 doi：10.1016 / j.dld.2019.01.011。 [印刷前的电子版]
白蛋白 - 胆红素（ALBI）作为慢性乙型肝炎相关肝硬化的准确和简单的预后评分。
Wang J1，Zhang Z1，Yan X1，Li M2，Xia J1，Liu Y3，Chen Y3，Jia B1，Zhu L2，Zhu C4，Huang R5，Wu C6。
作者信息

1
    南京大学医学院附属医院南京鼓楼医院感染科，江苏南京
2
    苏州市第五人民医院肝病科，江苏苏州
3
    南京大学医学院附属医院南京鼓楼医院检验科，江苏南京
4
    苏州市第五人民医院肝病科，江苏苏州电子地址：[email protected]。
五
    南京大学医学院附属医院南京鼓楼医院感染科，江苏南京电子地址：[email protected]。
6
    南京大学医学院附属医院南京鼓楼医院感染科，江苏南京电子地址：[email protected]。

抽象
背景：

开发白蛋白 - 胆红素（ALBI）评分以预测肝细胞癌患者的长期预后。我们旨在调查ALBI在预测慢性乙型肝炎相关性肝硬化（CHB-LC）严重程度和长期预后方面的表现。
方法：

2011年至2017年期间，CHB-LC患者从两个医疗中心招募。评估ALBI的预后表现，并与Child-Turcotte-Pugh（CTP），终末期肝病模型（MELD）和MELD整合钠（MELD）进行比较-Na）分数。
结果：

该研究招募了398名CHB-LC患者，随访患者的中位数为33.9（IQR 21.6-48.8）个月。 ALBI（HR：3.151,95％CI：2.039-4.869，P <0.001）被确定为肝脏相关死亡率的独立预测因子。受试者工作特征曲线（ROCs）分析显示，ALBI评分（0.756,0.745,0.739,0.767和0.765）优于MELD评分（P <0.05），与CTP评分（P> 0.05）相比预测2年， 3年，4年，5年和全球死亡率。 ALBI评分的AUROCs显着高于MELD-Na评分（P <0.05），用于预测2年，3年和5年死亡率。 ALBI评分较低的患者死亡率显着低于ALBI评分较高的患者（P <0.05）。
结论：

ALBI评分准确预测CHB-LC患者的严重程度和长期预后。 ALBI评分的预后表现优于MELD和MELD-Na评分。

版权所有©2019 Editrice Gastroenterologica Italiana S.r.l.由Elsevier Ltd.出版。保留所有权利。
关键词：

ALBI; CHB;死亡;无创标记;预测

结论：
    30765220
DOI：
    10.1016 / j.dld.2019.01.011